Lowest-Rated StocksLowest-RatedNASDAQ:BLUE bluebird bio (BLUE) Stock Price, News & Analysis $7.86 -0.92 (-10.48%) (As of 05:45 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About bluebird bio Stock (NASDAQ:BLUE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get bluebird bio alerts:Sign Up Key Stats Today's Range$7.75▼$8.5950-Day Range$5.89▼$14.7352-Week Range$5.80▼$38.40Volume346,852 shsAverage Volume396,795 shsMarket Capitalization$76.41 millionP/E RatioN/ADividend YieldN/APrice Target$49.14Consensus RatingHold Company Overviewbluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.Read More… bluebird bio Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks53rd Percentile Overall ScoreBLUE MarketRank™: bluebird bio scored higher than 53% of companies evaluated by MarketBeat, and ranked 516th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus Ratingbluebird bio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 2 buy ratings, 6 hold ratings, and 2 sell ratings.Amount of Analyst Coveragebluebird bio has only been the subject of 4 research reports in the past 90 days.Read more about bluebird bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for bluebird bio are expected to grow in the coming year, from ($1.35) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of bluebird bio is -4.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of bluebird bio is -4.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratiobluebird bio has a P/B Ratio of 4.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted26.76% of the float of bluebird bio has been sold short.Short Interest Ratio / Days to Coverbluebird bio has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in bluebird bio has recently decreased by 94.80%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend Yieldbluebird bio does not currently pay a dividend.Dividend Growthbluebird bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted26.76% of the float of bluebird bio has been sold short.Short Interest Ratio / Days to Coverbluebird bio has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in bluebird bio has recently decreased by 94.80%, indicating that investor sentiment is improving significantly. News and Social Media2.6 / 5News Sentiment0.69 News Sentimentbluebird bio has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for bluebird bio this week, compared to 5 articles on an average week.Search Interest22 people have searched for BLUE on MarketBeat in the last 30 days. This is an increase of 214% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added bluebird bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -22% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, bluebird bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $403.00 in company stock.Percentage Held by InsidersOnly 1.40% of the stock of bluebird bio is held by insiders.Percentage Held by Institutions87.43% of the stock of bluebird bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about bluebird bio's insider trading history. Receive BLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter. Email Address BLUE Stock News Headlinesbluebird bio, Inc. (BLUE): Is This Gene Therapy Stock a Good Buy Right Now?December 29 at 6:21 AM | insidermonkey.com2seventy bio: All In On Abecma Multiple Myeloma TreatmentDecember 23, 2024 | seekingalpha.comKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware of… yet have the potential to deliver colossal returns over the next four years. I’m not talking about Tesla, Palantir, or anything else you’ve heard parroted by the mainstream financial press. No. These are Trump’s Secret Stocks. December 30, 2024 | Porter & Company (Ad)bluebird bio, Inc. (NASDAQ:BLUE) Given Consensus Rating of "Hold" by BrokeragesDecember 23, 2024 | americanbankingnews.comStockNews.com Begins Coverage on bluebird bio (NASDAQ:BLUE)December 23, 2024 | americanbankingnews.comMarch Biosciences Elects Peter Olagunju as Chair of Board of DirectorsDecember 19, 2024 | markets.businessinsider.combluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and ExpositionDecember 8, 2024 | businesswire.comBluebird Bio participates in CMMI Cell and Gene Therapy Access ModelDecember 5, 2024 | markets.businessinsider.comSee More Headlines BLUE Stock Analysis - Frequently Asked Questions How have BLUE shares performed this year? bluebird bio's stock was trading at $27.60 on January 1st, 2024. Since then, BLUE stock has decreased by 71.5% and is now trading at $7.86. View the best growth stocks for 2024 here. How were bluebird bio's earnings last quarter? bluebird bio, Inc. (NASDAQ:BLUE) posted its quarterly earnings data on Tuesday, November, 7th. The biotechnology company reported ($13.20) earnings per share for the quarter, topping analysts' consensus estimates of ($13.80) by $0.60. bluebird bio's quarterly revenue was up 17364.8% on a year-over-year basis. When did bluebird bio's stock split? bluebird bio shares reverse split on Friday, December 13th 2024. The 1-20 reverse split was announced on Wednesday, December 4th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of bluebird bio? Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of bluebird bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that bluebird bio investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings11/07/2023Today12/30/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BLUE CUSIPN/A CIK1293971 Webwww.bluebirdbio.com Phone(339) 499-9300FaxN/AEmployees323Year FoundedN/APrice Target and Rating Average Stock Price Target$49.14 High Stock Price Target$120.00 Low Stock Price Target$10.00 Potential Upside/Downside+525.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($37.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-211,910,000.00 Net Margins-565.74% Pretax Margin-551.41% Return on Equity-322.46% Return on Assets-53.17% Debt Debt-to-Equity Ratio0.37 Current Ratio0.51 Quick Ratio0.33 Sales & Book Value Annual Sales$53.12 million Price / Sales1.44 Cash FlowN/A Price / Cash FlowN/A Book Value$1.78 per share Price / Book4.42Miscellaneous Outstanding Shares9,722,000Free Float191,722,000Market Cap$76.41 million OptionableOptionable Beta0.72 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:BLUE) was last updated on 12/30/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored>>>RE: Buy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share bluebird bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
